Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit
Seeking Alpha News (Fri, 3-May 3:00 PM ET)
TipRanks (Mon, 29-Apr 9:41 PM ET)
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Seeking Alpha News (Sun, 28-Apr 1:00 PM ET)
Business Wire (Fri, 26-Apr 4:13 PM ET)
PRNewswire (Tue, 23-Apr 12:45 AM ET)
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Business Wire (Thu, 18-Apr 8:00 AM ET)
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Business Wire (Wed, 10-Apr 4:01 PM ET)
Vertex to Announce First Quarter 2024 Financial Results on May 6
Business Wire (Tue, 9-Apr 4:05 PM ET)
Business Wire (Mon, 1-Apr 8:00 AM ET)
Business Wire (Thu, 21-Mar 8:00 AM ET)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.
As of May 3, 2024, VRTX stock price climbed to $401.08 with 1,011,587 million shares trading.
VRTX has a beta of 0.82, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.18 to the broad based SPY ETF.
VRTX has a market cap of $103.60 billion. This is considered a Large Cap stock.
Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.20 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.10.
In the last 3 years, VRTX stock traded as high as $448.40 and as low as $176.36.
The top ETF exchange traded funds that VRTX belongs to (by Net Assets): RAYD, VTI, VOO, QQQ, SPY.
VRTX has underperformed the market in the last year with a price return of +15.9% while the SPY ETF gained +26.1%. VRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.6% and +1.9%, respectively, while the SPY returned +3.7% and +2.4%, respectively.
VRTX support price is $395.00 and resistance is $405.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX stock will trade within this expected range on the day.